Hillstream BioPharma Announces Share Repurchase Program
June 13, 2022 08:00 ET
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”), a biotechnology company developing novel therapeutic candidates...
Hillstream BioPharma Provides Corporate Update
June 02, 2022 08:47 ET
|
Hillstream BioPharma, Inc.
Recent milestones include FDA Orphan Drug Designations for HSB-1216 and HSB-888 World-class scientific advisory team and growing and distinguished patent portfolio remain key competitive advantages...
Hillstream BioPharma to Present at BioNJ's 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022
May 05, 2022 08:47 ET
|
Hillstream BioPharma, Inc.
Developed in partnership with J.P. Morgan and Johnson & Johnson Innovation, the Conference will bring together more than 500 life sciences professionals and thought leadersHillstream’s...
Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II
May 19, 2020 08:00 ET
|
Hillstream BioPharma, Inc.
CHESTER, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”) today announced that two abstracts highlighting the progress of HSB-1216 (salinomycin QUATRAMER™)...
Hillstream BioPharma Granted Orphan Drug Designation for HSB-1216 (QUATRAMER Salinomycin) for Treatment of Small Cell Lung Cancer (SCLC)
January 06, 2020 08:00 ET
|
Hillstream BioPharma, Inc.
Positive pre-clinical data with an emerging validated mechanism of action, Ferroptosis HSB-1216 is a novel therapeutic using the QUATRAMER formulation of a potent anti-Ferroptotic compounds,...
Hillstream BioPharma Announces Kwok-Kin Wong, MD, PhD as New Member to Scientific Advisory Board
November 19, 2019 07:00 ET
|
Hillstream BioPharma, Inc.
CHESTER, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma Inc. (“Hillstream”) today announced the addition of clinician-scientist Kwok-Kin Wong, MD, PhD to Hillstream’s Scientific...
Hillstream BioPharma Announces Collaboration with Ardena to Support QUATRAMER Manufacturing
November 04, 2019 09:35 ET
|
Hillstream BioPharma, Inc.
CHESTER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”) today announced a collaboration with Ardena to secure manufacturing feasibility and capacity for...
Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of QUATRAMER™ Drug Delivery Technology with HDAC6-PI3Kδ Dual Inhibitor for AML
October 10, 2019 09:35 ET
|
Hillstream BioPharma, Inc.
CHESTER, N.J., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma Inc. (“Hillstream”) today announced the renewal of a Cooperative Research and Development Agreement (CRADA) with the National...
Hillstream BioPharma Presents at 2017 Marcum MicroCap Conference in New York
June 12, 2017 12:40 ET
|
Hillstream Biosciences
CHESTER, N.J., June 12, 2017 (GLOBE NEWSWIRE) -- Hillstream BioPharma Inc. (Hillstream), a biopharmaceutical company focused on developing targeted, safer and more effective cancer therapeutics,...